CCMH
CBIO icon

Cornerstone Capital Management Holdings’s Crescent Biopharma CBIO Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-13
Closed -$9K – 1361
2016
Q3 		$9K Buy
+13
New +$9.95K ﹤0.01% 1340

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Cornerstone Capital Management Holdings's CBIO Position: Q4 2016 in Review

Cornerstone Capital Management Holdings sold out of Crescent Biopharma (CBIO) in Q4 2016, closing a stake of 13 shares — an estimated $9K sold.

Cornerstone Capital Management Holdings first reported a position in CBIO in Q3 2016 and held it in 1 quarter. The position peaked at $9K in Q3 2016. 50 funds tracked by Wall St. Rank hold CBIO as of Q4 2016.

  • Cornerstone Capital Management Holdings reported no remaining Crescent Biopharma position as of Q4 2016 after selling out during the quarter.
  • Cornerstone Capital Management Holdings sold 13 Crescent Biopharma shares in Q4 2016, an estimated $9K.
  • Cornerstone Capital Management Holdings first reported a position in Crescent Biopharma in Q3 2016 and held it in 1 quarter.
  • Cornerstone Capital Management Holdings's Crescent Biopharma position peaked at $9K in Q3 2016.
  • 50 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2016.

Based on Cornerstone Capital Management Holdings's 13F filing for Q4 2016, filed 14 Feb 2017.